Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK).

Abstract

Peripheral T-cell lymphomas (PTCLs) are an uncommon and heterogeneous group of well-differentiated, post-thymic T-cell malignancies that can present in the skin as cutaneous T-cell lymphomas. In general, their prognosis is poor, and specific therapy is not well defined. We report the successful treatment of a patient with relapsed, refractory PTCL who after failing 13 standard single and multiple chemotherapy regimens and experimental agents had a dramatic prolonged response to diftitoxin denileukin (ONTAK). This fusion protein, composed of diphtheria toxin coupled to interleukin-2, is approved for cutaneous T-cell lymphomas, including mycosis fungoides, and should be considered for treatment of the rare subset of peripheral T-cell lymphomas.

• Authors: Rakhshandra Talpur, Narin Apisarnthanarax, Staci Ward, Madeleine Duvic
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 43 Issue 1 Pg. 121-6 (Jan 2002) ISSN: 1042-8194 [Print] United States
• PMID: 11908715 (Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Diphtheria Toxin
• Interleukin-2
• Receptors, Interleukin-2
• Recombinant Fusion Proteins
• denileukin diftitox

Topics

• Aged
• Antineoplastic Agents (administration & dosage, therapeutic use)
• Diphtheria Toxin (administration & dosage, therapeutic use)
• Erythema (etiology)
• Humans
• Interleukin-2 (administration & dosage, therapeutic use)
• Lung Neoplasms (drug therapy, pathology)
• Lymph Nodes (pathology)
• Lymphoma, T-Cell, Peripheral (drug therapy, pathology)
• Male
• Nose Neoplasms (drug therapy, pathology)
• Receptors, Interleukin-2 (drug effects, metabolism)
• Recombinant Fusion Proteins (administration & dosage, therapeutic use)
• Salvage Therapy
• Skin Neoplasms (drug therapy, pathology)
• Treatment Outcome